PET of brain amyloid and tau in mild cognitive impairment

Department of Psychiatry and Biobehavioural Sciences, University of California, Los Angeles, Los Ángeles, California, United States
New England Journal of Medicine (Impact Factor: 54.42). 12/2006; 355(25):2652-63. DOI: 10.1056/NEJMoa054625
Source: PubMed

ABSTRACT Amyloid senile plaques and tau neurofibrillary tangles are neuropathological hallmarks of Alzheimer's disease that accumulate in the cortical regions of the brain in persons with mild cognitive impairment who are at risk for Alzheimer's disease. Noninvasive methods to detect these abnormal proteins are potentially useful in developing surrogate markers for drug discovery and diagnostics.
We enrolled 83 volunteers with self-reported memory problems who had undergone neurologic and psychiatric evaluation and positron-emission tomography (PET). On the basis of cognitive testing, 25 volunteers were classified as having Alzheimer's disease, 28 as having mild cognitive impairment, and 30 as having no cognitive impairment (healthy controls). PET was performed after injection of 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile (FDDNP), a molecule that binds to plaques and tangles in vitro. All subjects also underwent 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET, and 72 underwent magnetic resonance imaging (MRI).
Global values for FDDNP-PET binding (average of the values for the temporal, parietal, posterior cingulate, and frontal regions) were lower in the control group than in the group with mild cognitive impairment (P<0.001), and the values for binding in the group with mild cognitive impairment were lower than in the group with Alzheimer's disease (P<0.001). FDDNP-PET binding differentiated among the diagnostic groups better than did metabolism on FDG-PET or volume on MRI.
FDDNP-PET scanning can differentiate persons with mild cognitive impairment from those with Alzheimer's disease and those with no cognitive impairment. This technique is potentially useful as a noninvasive method to determine regional cerebral patterns of amyloid plaques and tau neurofibrillary tangles.


Available from: Helen Lavretsky, Apr 18, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hereditary frontotemporal dementia (FTD) associated with mutations in the Microtubule Associated Protein Tau gene (MAPT) is a protean disorder. Three neuropathologic subtypes can be recognized, based on the presence of inclusions made of tau isoforms with 3 and 4 repeats, predominantly 3 repeats and mostly 4 repeats. This is relevant for establishing a correlation between structural magnetic resonance imaging and positron emission tomography using tracers specific for aggregated tau. Longitudinal studies will be essential to determine the evolution of anatomical alterations from the asymptomatic stage to the various phases of disease following the onset of symptoms.
    Neuropathology and Applied Neurobiology 12/2014; 41(1). DOI:10.1111/nan.12213 · 4.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Increasing evidence indicates that blood-brain barrier (BBB) impairment may play a role in the pathophysiology of cognitive decline and dementia. In vivo imaging studies are needed to quantify and localize the BBB defects during life, contemplating the circulatory properties. We reviewed the literature for imaging studies investigating BBB impairment in patients suffering from dementia. After selection, 11 imaging studies were included, of which 6 used contrast-enhanced magnetic resonance imaging (MRI), 2 used contrast-enhanced computed tomography (CT), and 3 positron emission tomography (PET). Primarily the MRI studies hint at a subtle increasing permeability of the BBB, particularly in patients already exhibiting cerebrovascular pathology. More elaborate studies are required to provide convincing evidence on BBB impairment in patients with various stages of dementia with and without obvious cerebrovascular pathology. In the future, dynamic contrast enhanced MRI techniques and transport specific imaging using PET may further detail the research on the molecular nature of BBB defects. Copyright © 2014. Published by Elsevier Ltd.
    Neuroscience & Biobehavioral Reviews 02/2015; 49:71-81. DOI:10.1016/j.neubiorev.2014.11.022 · 10.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: IBTs (imidazo[2,1-b]benzothiazoles) are a promising novel class of amyloid PET radiopharmaceuticals for diagnosis of neurodegenerative disorders like Alzheimer's disease (AD). Their good in vivo imaging properties have previously been shown in preclinical studies. Among IBTs, fluorinated [18F]FIBT was selected for further characterization and advancement towards use in humans. [18F]FIBT characteristics were analyzed in relation to Pittsburgh compound B (PiB) as reference ligand. [18F]FIBT and [3H]PiB were co-injected to an APP/PS1 mouse for ex vivo dual-label autoradiographic correlation. Acute dose toxicity of FIBT was examined in two groups of healthy mice. Preexisting in vivo stability and biodistribution studies in mice were complemented with analogous studies in rats. [18F]FIBT was titrated against post-mortem human AD brain homogenate in a saturation binding assay previously performed with [3H]PiB. Binding of [18F]FIBT to human AD brain was further analyzed by in vitro incubation of human AD brain sections in comparison to [11C]PiB and standard immunohistochemistry. Finally, [18F]FIBT was administered to two human subjects for a dynamic 90-min PET/MR brain investigation. Ex vivo autoradiography confirmed good uptake of [18F]FIBT to mouse brain and its excellent correlation to [3H]PiB binding. No toxicity of FIBT could be found in mice at a concentration of 33.3 nmol/kg. As in mice, [18F]FIBT was showing high in vivo stability in rats and comparable regional brain biodistribution dynamics to [3H]PiB. Radioligand saturation binding confirmed at least one high-affinity binding component of [18F]FIBT around 1 nM. Good binding of FIBT relative to PiB was further confirmed in binding assays and autoradiography using post-mortem AD brain. First use of [18F]FIBT in humans successfully yielded clinical [18F]FIBT PET/MR images with very good contrast. In summary, [18F]FIBT has been characterized to be a new lead compound with improved binding characteristics and pharmacokinetics on its own as well as in comparison to PiB. A pilot human PET investigation provided high-quality images with a plausible tracer distribution pattern. Detailed clinical investigations are needed to confirm these first results and to explore the specific qualities of [18F]FIBT PET for dementia imaging in relation to established ligands.
    ACS Chemical Neuroscience 12/2014; DOI:10.1021/cn5001827 · 4.21 Impact Factor

Similar Publications